Inflammatory skin diseases remain a significant therapeutic challenge due to their chronic course, tendency to relapse, and the need for long-term topical treatment. In response to these limitations, the present study focuses on developing a novel dermatological hydrogel intended as a carrier for lipid-based nanoformulations containing plant-derived active compounds with anti-inflammatory potential.
The hydrogel matrix was designed through qualitative and quantitative optimization of the gelling agent and preservative system. Preservatives were selected based on compliance with the preservative efficacy test defined in the European Pharmacopoeia. Physicochemical characterization of the base included measurements of pH, density, and viscosity. Rheological analysis confirmed a non‑Newtonian behavior with pseudoplastic traits, as indicated by the viscosity–shear rate relationship in a plate–plate measurement system (25 °C). The pH values remained unchanged during a two-month storage period under both room and refrigerated conditions.
Subsequently, lipid nanoformulations encapsulating a mixture of active pharmaceutical ingredients were incorporated into the hydrogel. The process led to gel thickening, highlighting the importance of selecting an appropriate gelling agent concentration during the initial testing phase. Despite this, the final formulation demonstrated a homogeneous structure and suitable consistency for topical application. Cryo-TEM imaging and nanoparticle tracking analysis verified the presence and integrity of nanoparticles within the hydrogel matrix. The final hydrogel demonstrated stability with respect to pH and visual appearance throughout the storage period (2 months at 4 °C and 25 °C), supporting its potential application in dermatological therapy for inflammatory skin disorders. The developed system constitutes a promising platform for further biological and pharmacological evaluation.
Funding: Research aimed at developing a new, innovative pharmaceutical form for the topical treatment of psoriasis vulgaris is being implemented as part of the National Recovery and Resilience Plan, as part of Investment D3.1.1 Comprehensive development of research in medical sciences and health sciences, reference number: 2024/ABM/03/KPO/KPOD.07.07-IW.07-0043/24-00.
